Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparative study to assess the effect of retreatment with 2 doses of MabThera on disease activity score in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to antiTNF-alfa therapy (SMART)

Trial Profile

A comparative study to assess the effect of retreatment with 2 doses of MabThera on disease activity score in patients with active rheumatoid arthritis who have had an inadequate response or intolerance to antiTNF-alfa therapy (SMART)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SMART
  • Sponsors Roche
  • Most Recent Events

    • 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 22 Nov 2011 Primary endpoint 'C-reactive-protein' has been met according to 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals.
    • 22 Nov 2011 Primary endpoint 'Disease-activity-score' has been met according to 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top